

CONTACT: Brian Bennett  
(501)225-9733



*(For Immediate Release)*

## **i3 ADDS APPOINTMENTS TO KEY LEADERSHIP POSITIONS**

**BASKING RIDGE, NJ, January 7, 2010**—Pharmaceutical services company i3 announced today its appointment of Brian Kelly as group president for its i3 Innovus, i3 Drug Safety, and i3 Pharma Informatics business units, and Tracy Ken Tsuetaki, OD, as president of i3 Research. i3 also announced the appointment of Andrew Chong as regional vice president for i3 in the Asia Pacific region.

Brian Kelly's appointment will enable the existing business unit presidents of i3 Innovus, Drug Safety and Pharma Informatics to help drive strategic focus across the units while maintaining the distinctive brands of each. Kelly was global vice president and general manager in Covance's Central Laboratory Services business. Before that he spent nine years at Merck, leaving as vice president of research planning and integration. His leadership experience began during his service as a naval officer and spans both large and small firms, including venture-stage Cytometrics and conglomerate E.I. DuPont.

Dr. Tsuetaki joins i3 from Covance, where he was chief marketing officer and a corporate vice president. Prior to that, he served as group president of Catalent Pharma Solutions; division president and a senior vice president of Global Business Development for Quintiles Transnational; and non-executive chairman of the Board of Directors for Laureate Pharma, Inc. He holds a Doctorate of Optometry from the University of California, among many other degrees, including an MBA from Northwestern University's Kellogg School of Management, and will bring a unique combination of scientific, business and marketing skills.

Andrew Chong's appointment emphasizes the commitment that i3 has made to the strategically important Asia Pacific region. He brings two decades of experience in the biopharmaceutical industry in clinical drug development; drug discovery research and medical affairs; and functional management. Chong comes to i3 from Genentech, where he led the Asia Pacific region in the Office of International Development.

### **About i3**

i3 takes a 360-degree view of healthcare to help its global pharmaceutical, biotechnology, and medical device customers bring safe and effective products to market quickly and help demonstrate their value, leading to increased ROI and better patient care. i3's integrated businesses combine a deep understanding of data and methodologies; therapeutic, scientific, and functional proficiency; and the expertise to help design research that demonstrates a product's value, and helps achieve market access and assure reimbursement. More information about i3 can be obtained at [www.i3global.com](http://www.i3global.com).

# # #